Corporate Misconduct Accountability Project
Alexion Pharmaceuticals, Inc. · Securities class action and SEC enforcement
Alexion Pharmaceuticals Accused of Global Corruption Scheme
SEC investigated alleged bribery and misconduct to secure government coverage for a $700,000 per patient drug. Shareholders sued after company concealed the investigation.
CRITICAL SEVERITY
TL;DR
Alexion Pharmaceuticals marketed Soliris, a rare disease drug costing up to $700,000 per patient annually. The SEC investigated whether Alexion violated the Foreign Corrupt Practices Act by funneling grants to foreign patient advocacy groups to pressure governments into covering the drug. Shareholders sued, alleging the company concealed this investigation and engaged in illegal sales tactics worldwide. Alexion paid $21.5 million to settle with the SEC and $125 million to settle the shareholder lawsuit.
This case shows how pharmaceutical giants exploit rare disease patients for profit while evading oversight across borders.
$700K
Annual cost per patient for Soliris treatment
11,000
Estimated worldwide Soliris patients in 2017
$125M
Shareholder securities class action settlement
$21.5M
SEC settlement amount paid by Alexion
The Allegations: A Breakdown
Core Allegations
What they did · 8 points
| 01 | The SEC investigated Alexion for possible violations of federal securities laws involving inaccurate annual reports and failure to maintain adequate books and records. The investigation focused on compliance with the Foreign Corrupt Practices Act, including gifts and payments to public health institutions and government agents. | high |
| 02 | Alexion allegedly funneled grants to patient advocacy groups in Brazil, who then used the money to file lawsuits forcing the Brazilian government to reimburse patients for Soliris. This allowed Alexion to secure government payment without directly negotiating prices. | high |
| 03 | The company allegedly obtained data from partner laboratories to identify potential Soliris customers before anyone else, then deployed extreme fear tactics to pressure patients into demanding the drug from insurers and health services. | high |
| 04 | Alexion allegedly engaged in improper lobbying and grant-making activities in Japan, Brazil, Russia, and Turkey to secure favorable treatment and reimbursement for Soliris. The SEC subpoena specifically sought documents on these activities and compliance with anti-bribery laws. | high |
| 05 | Shareholders alleged Alexion violated securities laws by making misleading statements and omissions about its business practices. The company allegedly concealed its illegal and unethical sales tactics, which included funding foreign organizations to influence government healthcare policy. | high |
| 06 | The securities class action complaint alleged that Alexion improperly issued grants to patient advocacy groups in Brazil to sue the government for Soliris reimbursements, rather than directly negotiate prices with the Brazilian government. This constituted a sustained pattern of illegal and unethical conduct. | high |
| 07 | Alexion allegedly failed to disclose material information to investors about the SEC investigation and the legal risks the company faced from its overseas sales and marketing practices. This allowed stock prices to remain artificially inflated. | medium |
| 08 | The company allegedly recalled certain lots of Soliris but failed to accurately disclose information about the recall in its securities filings. The SEC subpoena sought all documents relating to statements regarding the recall and related securities disclosures. | medium |
Regulatory Failures
Where oversight broke down · 5 points
| 01 | The SEC did not issue its formal investigation order against Alexion until March 2015, despite years of alleged misconduct. By the time regulators acted, the company had already secured billions in revenue from questionable practices. | high |
| 02 | Multiple countries including Brazil, Japan, Russia, and Turkey allowed Alexion to operate with minimal scrutiny of its grant-making and lobbying activities. The lack of coordinated international enforcement enabled the alleged corruption scheme to continue across borders. | high |
| 03 | The insurance coverage dispute revealed that even after Alexion disclosed the SEC investigation to its insurers in 2015, no immediate regulatory action halted the company’s practices. The alleged misconduct continued for over a year until shareholders filed suit in December 2016. | medium |
| 04 | The Superior Court initially sided with Alexion, finding the link between the SEC investigation and the securities class action too tenuous to trigger the earlier insurance policy. This decision was only reversed on appeal, demonstrating how lower courts can fail to recognize patterns of corporate wrongdoing. | medium |
| 05 | Regulatory agencies faced challenges investigating Alexion’s global operations across multiple jurisdictions with different healthcare systems. Gathering evidence from Brazil, Turkey, Russia, and Japan involved slow-moving legal processes and cross-border data requests. | medium |
Profit Over People
The financial incentive for harm · 6 points
| 01 | Soliris generated revenue of $500,000 to $700,000 per patient annually. With approximately 11,000 patients worldwide, the drug produced billions in revenue, creating enormous financial incentive to expand coverage by any means necessary. | high |
| 02 | Alexion’s settlement payments of $125 million to shareholders and $21.5 million to the SEC totaled $146.5 million. These amounts likely represented a fraction of the profits generated from years of alleged misconduct, making the settlements merely a cost of doing business. | high |
| 03 | The company allegedly warned its insurers that government investigations could result in consequences and substantial expenses. Despite this awareness of legal risks, Alexion continued its aggressive overseas expansion strategy to maximize Soliris revenue. | high |
| 04 | Alexion’s insurance dispute centered on whether coverage fell under an $85 million policy or a $105 million policy. The company fought to access the higher coverage limit, demonstrating that even settlement costs were carefully managed to minimize financial impact on the corporation. | medium |
| 05 | The alleged fear-based marketing tactics exploited vulnerable patients with life-threatening rare diseases. Sales representatives emphasized dire consequences if patients discontinued treatment, effectively cornering families into demanding the drug regardless of cost. | high |
| 06 | Publicly traded pharmaceutical companies face constant investor pressure for quarterly earnings growth. This pressure can incentivize executives to engage in legally questionable practices if the potential profits dwarf eventual fines or settlements. | medium |
Economic Fallout
Who paid the price · 6 points
| 01 | National healthcare systems in countries like Brazil were allegedly forced to divert limited healthcare resources to cover Soliris treatments costing up to $700,000 per patient. This left fewer resources for other essential medical services that could have served more people. | high |
| 02 | Government health agencies faced a binary choice imposed by Alexion’s pricing strategy: pay enormous sums for Soliris or deny coverage to patients with fatal conditions. This effectively held entire healthcare systems hostage to corporate pricing demands. | high |
| 03 | Insurers who covered Soliris passed costs to consumers through higher premiums. In single-payer systems, taxpayers absorbed the burden. Either way, the economic impact extended far beyond the small number of patients actually receiving treatment. | high |
| 04 | Alexion’s alleged practice of funding lawsuits through patient advocacy groups externalized the cost of market expansion onto foreign governments. The company gained revenue while public health budgets in developing nations faced additional strain. | high |
| 05 | The insurance coverage dispute itself generated substantial legal costs as multiple insurers and Alexion fought over which policy would cover the settlements. These litigation expenses ultimately increased insurance costs across the industry. | medium |
| 06 | Lower-income countries struggled or failed entirely to provide coverage for Soliris due to its astronomical price. This created a wealth-based disparity in access to life-saving treatment, where only patients in wealthy nations or with exceptional insurance could afford therapy. | high |
Public Health and Safety
The human cost · 5 points
| 01 | Patients with rare genetic diseases faced extreme vulnerability to Alexion’s alleged fear-based marketing. The company’s sales representatives reportedly contacted patients directly and emphasized dire consequences if they did not continue treatment, exploiting families’ anxieties about fatal conditions. | high |
| 02 | The alleged manipulation of healthcare policy through funded lawsuits compromised the integrity of medical decision-making. Governments made coverage decisions based on legal pressure rather than cost-effectiveness analysis or public health priorities. | high |
| 03 | Alexion allegedly obtained patient data from partner laboratories without proper safeguards, raising concerns about medical privacy violations. The company used this data to identify and aggressively pursue potential Soliris customers before they could consider alternatives. | medium |
| 04 | The SEC investigation examined whether Alexion provided accurate information about Soliris recalls in its public disclosures. Incomplete or misleading information about drug safety issues could have prevented patients and doctors from making fully informed treatment decisions. | medium |
| 05 | Healthcare resources diverted to cover ultra-expensive Soliris treatments meant less funding for preventive care, chronic disease management, and treatments serving larger patient populations. The opportunity cost of covering one Soliris patient could fund care for hundreds of others. | high |
Corporate Accountability Failures
The accountability gap · 7 points
| 01 | Alexion settled both the SEC enforcement action and the shareholder lawsuit without admitting wrongdoing. This allowed the company to avoid a trial that would have publicly aired more details about its alleged misconduct while facing no formal admission of liability. | high |
| 02 | The Delaware Supreme Court reversed the lower court’s decision, finding that the securities class action was meaningfully linked to the SEC investigation disclosed in 2015. The initial ruling had incorrectly allowed Alexion to escape the consequences of its earlier notice to insurers. | high |
| 03 | No individual executives faced criminal charges despite serious allegations of Foreign Corrupt Practices Act violations. The settlements focused on corporate financial penalties rather than personal accountability for decision-makers who allegedly approved the misconduct. | high |
| 04 | Alexion’s internal compliance systems allegedly failed to prevent or detect widespread misconduct across multiple countries over several years. The company’s board of directors and audit committees did not stop practices that eventually triggered major government investigations. | high |
| 05 | The insurance carrier Chubb initially accepted Alexion’s coverage under the more favorable Tower 2 policy but later attempted to reassign it to Tower 1. This demonstrates how even insurers tasked with monitoring risk failed to properly assess the scope of Alexion’s disclosed liabilities. | medium |
| 06 | Years passed between Alexion’s alleged misconduct beginning and the SEC issuing its formal investigation order in March 2015. This gap allowed the company to profit from questionable practices for an extended period before facing any regulatory scrutiny. | high |
| 07 | The Superior Court initially treated Alexion’s 2015 notice to insurers as a claim rather than as disclosure of circumstances that might give rise to future claims. This legal error nearly allowed Alexion to access more favorable insurance coverage and avoid full accountability. | medium |
The PR Machine
How they controlled the narrative · 4 points
| 01 | Alexion likely issued carefully worded statements expressing cooperation with investigations while avoiding any admission of wrongdoing. This standard corporate crisis response allows companies to appear transparent while protecting themselves legally. | medium |
| 02 | The settlements allowed Alexion to resolve both matters without a trial that would have generated extensive negative publicity. By paying to make the cases go away, the company avoided weeks or months of damaging headlines about alleged corruption and misconduct. | medium |
| 03 | Pharmaceutical companies typically pivot to patient-centered narratives after scandals, highlighting success stories and research initiatives. This strategy helps overshadow controversies by reminding the public of the drug’s life-saving potential. | medium |
| 04 | Alexion framed both settlements as pragmatic steps to put matters behind the company and focus on serving patients. This messaging minimized the significance of paying nearly $150 million to resolve allegations of serious misconduct. | medium |
Wealth Disparity
Who gained and who lost · 5 points
| 01 | Alexion’s shareholders and executives profited from billions in Soliris revenue during the period of alleged misconduct. Meanwhile, patients in lower-income countries either went without treatment or forced their governments to divert scarce healthcare funds to cover the drug. | high |
| 02 | The $700,000 annual cost per patient created a two-tier system where only patients in wealthy nations or with exceptional insurance could access Soliris. This pricing structure exacerbated global health inequality and tied survival to economic status. | high |
| 03 | Public healthcare systems absorbed the cost of Alexion’s alleged market manipulation while the company and its investors captured the financial gains. This transferred wealth from taxpayers and public health budgets to corporate shareholders and executives. | high |
| 04 | Even after settling for $146.5 million combined, Alexion likely retained substantial profits from years of Soliris sales. The settlements represented a small fraction of total revenue, meaning shareholders still came out far ahead despite the legal consequences. | high |
| 05 | Healthcare spending on Soliris for 11,000 patients at $700,000 each would total $7.7 billion annually. This massive concentration of resources on a single drug for a small patient population demonstrates extreme resource allocation inequality in global healthcare. | high |
The Bottom Line
What this means · 6 points
| 01 | The Delaware Supreme Court ruled that Alexion’s securities class action was meaningfully linked to the SEC investigation disclosed in 2015. Coverage must therefore fall under the earlier Tower 1 insurance policy with lower limits, forcing Alexion to bear more of the settlement costs. | high |
| 02 | Both the SEC investigation and the shareholder lawsuit involved the same underlying conduct: Alexion’s alleged improper grant-making, lobbying, and sales tactics to secure government coverage for Soliris worldwide. The common wrongful acts established the meaningful linkage between the claims. | high |
| 03 | Alexion’s 2015 notice to insurers explicitly warned that government investigations into FCPA compliance could result in private litigation and substantial expenses. This notice disclosed the circumstances that later gave rise to the securities class action, triggering the earlier policy. | high |
| 04 | The case demonstrates how pharmaceutical companies can exploit rare disease patients for profit while evading oversight across multiple countries. Without coordinated international enforcement and stronger penalties, such patterns of alleged misconduct will continue. | high |
| 05 | Settlement structures that allow companies to pay fines without admitting wrongdoing create moral hazard. Alexion resolved both matters for amounts that likely pale in comparison to the profits generated from alleged misconduct, making the penalties just another cost of business. | high |
| 06 | The insurance dispute itself revealed how corporations meticulously manage legal risk and settlement costs. Alexion fought to access higher insurance coverage limits, demonstrating that even companies facing serious allegations prioritize minimizing financial impact over accountability. | medium |
Timeline of Events
March 2015
SEC issues formal investigation order against Alexion for possible securities law violations, FCPA compliance failures, and inadequate internal controls.
May 2015
SEC serves Alexion with subpoena demanding documents on grant-making activities, FCPA compliance, lobbying in Brazil, Japan, Russia, Turkey, and statements about Soliris recalls.
June 2015
Alexion sends notice to Tower 1 insurers disclosing SEC subpoena and warning of possible future litigation and substantial expenses from compliance investigations.
December 2016
Shareholders file federal securities class action in Connecticut alleging Alexion violated securities laws through illegal sales tactics and misleading statements.
January 2017
Alexion notifies Tower 2 insurers of securities class action. Primary insurer Chubb initially accepts coverage under Tower 2.
October 2018
Chubb reassigns coverage for securities class action to Tower 1, citing meaningful linkage to circumstances disclosed in 2015 notice.
July 2020
Alexion settles SEC enforcement action for $21.5 million without admitting or denying wrongdoing.
September 2023
Alexion settles shareholder securities class action for $125 million.
February 2024
Delaware Superior Court rules securities class action unrelated to 2015 notice, placing coverage in Tower 2.
November 2024
Delaware Supreme Court hears appeal from Tower 2 insurers arguing securities class action should be covered under Tower 1.
February 2025
Delaware Supreme Court reverses Superior Court, finding meaningful linkage between securities class action and 2015 notice. Coverage falls under Tower 1.
Direct Quotes from the Legal Record
QUOTE 1
SEC investigation scope
allegations
“The SEC Investigation Order raised possible violations of the federal securities laws involving inaccurate annual 8-K, 10-K, and 10-Q reports; failure to maintain adequate books and records; failure to maintain an adequate system of internal accounting controls; and bribing foreign officials and political parties.”
💡 The SEC investigated Alexion for serious violations including potential bribery of foreign officials under the Foreign Corrupt Practices Act.
QUOTE 2
Subpoena focus on corruption
allegations
“The SEC Subpoena sought all documents relating to Alexion’s grant-making worldwide; statements regarding the recall of certain lots of Soliris; compliance with the Foreign Corrupt Practices Act (FCPA), including gifts and payments to public health institutions and government agents; and lobbying efforts worldwide, especially in Japan, Brazil, Russia, and Turkey.”
💡 The SEC specifically investigated whether Alexion bribed foreign officials through grants and payments to secure favorable treatment for Soliris.
QUOTE 3
Warning of future litigation
accountability
“Any determination that Alexion’s operations or activities are not, or were not, in compliance with existing United States or foreign laws or regulations, including by the SEC pursuant to its investigation of Alexion’s compliance with the FCPA and other matters, could result in consequences to one more of the insureds. Other internal or government investigations or legal or regulatory proceedings, including lawsuits brought by private litigations may also follow as a consequence.”
💡 Alexion explicitly warned its insurers in 2015 that the SEC investigation could lead to private lawsuits, which is exactly what happened.
QUOTE 4
Alleged Brazil grant scheme
allegations
“The plaintiffs alleged that Alexion improperly issued grants to patient advocacy groups in Brazil to sue the government for reimbursements for Soliris, rather than directly negotiate the price of Soliris with the Brazilian government.”
💡 Shareholders alleged Alexion used grants to foreign organizations as a backdoor method to force governments to pay for the drug.
QUOTE 5
Pattern of illegal conduct
allegations
“They also alleged that, despite Alexion’s efforts to cover up the Company’s misconduct, the truth continued to slowly reveal itself through partial disclosures.”
💡 Shareholders claimed Alexion actively tried to hide its misconduct from investors while the truth gradually emerged.
QUOTE 6
Extreme sales tactics
profit
“These practices eventually attracted the attention of the Securities and Exchange Commission. Alexion allegedly engaged in extreme business practices. They cited a series of unethical and illegal sales and lobbying practices, including obtaining data from partner labs to identify potential customers, deploying extreme fear tactics to garner patients, and funding foreign organizations.”
💡 The court record describes Alexion’s sales methods as extreme, unethical, and illegal, including fear-based tactics targeting vulnerable patients.
QUOTE 7
Meaningful linkage standard
accountability
“We interpret arises out of, and other similar terms, as requiring some meaningful linkage between the two conditions imposed in the contract. Although these terms are paradigmatically broad, and we interpret them broadly, the linkage must be meaningful and not tangential.”
💡 The Supreme Court established that insurance coverage depends on a meaningful, not tangential, link between disclosed circumstances and later claims.
QUOTE 8
Supreme Court finding
conclusion
“We find, however, that the securities class action arose out of the circumstances disclosed by Alexion to its first tower insurers. Coverage should have been placed in the first tower.”
💡 The Delaware Supreme Court ruled the securities lawsuit was directly connected to what Alexion disclosed in 2015, requiring coverage under the earlier policy.
QUOTE 9
Common wrongful acts
conclusion
“Both investigations involved the same Wrongful Act: Alexion’s grantmaking activities. A meaningful linkage exists between the Securities Class Action and the SEC investigation as disclosed by Alexion in its 2015 Notice.”
💡 The court found both the SEC probe and shareholder lawsuit centered on the same underlying misconduct: improper grant-making to expand Soliris coverage.
QUOTE 10
Soliris patient numbers and cost
profit
“Soliris had about 11,000 customers worldwide. Soliris had a retail price of $500,000 to $700,000 for each patient.”
💡 With only 11,000 patients paying up to $700,000 each, Soliris generated billions in revenue despite serving a tiny population.
QUOTE 11
Settlement amounts
accountability
“On July 2, 2020, Alexion settled with the SEC for about $21.5 million. On September 12, 2023, Alexion settled the Securities Class Action for $125 million.”
💡 Alexion paid nearly $150 million to resolve both matters but admitted no wrongdoing, treating the settlements as a business expense.
QUOTE 12
Insurance coverage gap
accountability
“Although the Securities Class Action Settlement exceeded the coverage limits of each tower, Tower 2 provided $20 million more coverage than Tower 1. Thus, Alexion had an economic incentive to pursue coverage for the Securities Class Action under Tower 2.”
💡 Alexion fought to access higher insurance limits to minimize the financial impact of settlements, showing how corporations manage legal costs strategically.
Frequently Asked Questions
What did Alexion Pharmaceuticals allegedly do wrong?
Alexion allegedly violated the Foreign Corrupt Practices Act by funneling grants to foreign patient advocacy groups who then pressured governments to cover Soliris. The SEC also investigated whether Alexion failed to maintain proper accounting controls, made inaccurate securities filings, and engaged in fear-based marketing tactics to expand sales of its $700,000 per patient drug.
How much does Soliris cost and why does that matter?
Soliris costs between $500,000 and $700,000 per patient annually. This extreme price creates enormous financial incentive for Alexion to secure government and insurance coverage by any means necessary. It also means healthcare systems must divert substantial resources to cover a small number of patients, potentially leaving less funding for treatments that could help more people.
What countries were involved in the alleged misconduct?
The SEC investigation specifically examined Alexion’s activities in Brazil, Japan, Russia, and Turkey. The company allegedly funded patient advocacy groups and lobbying efforts in these countries to pressure governments into covering Soliris at its full retail price.
How much did Alexion pay to settle these cases?
Alexion paid $21.5 million to settle the SEC enforcement action and $125 million to settle the shareholder securities class action, totaling nearly $150 million. Importantly, the company did not admit wrongdoing as part of either settlement.
What was the insurance dispute about?
The dispute centered on whether the shareholder lawsuit should be covered under Alexion’s 2014-2015 insurance policy (Tower 1) with $85 million coverage, or its 2015-2017 policy (Tower 2) with $105 million coverage. Tower 2 insurers argued the lawsuit was linked to circumstances Alexion disclosed in 2015, while Alexion wanted the higher coverage limits of Tower 2.
What did the Delaware Supreme Court decide?
The Delaware Supreme Court ruled in February 2025 that the securities class action was meaningfully linked to the SEC investigation Alexion disclosed to insurers in 2015. This means coverage falls under Tower 1, the earlier policy with lower limits, forcing Alexion to bear more of the settlement costs.
Why did the court say the cases were linked?
The court found both the SEC investigation and shareholder lawsuit involved the same underlying wrongful acts: Alexion’s grant-making activities, FCPA compliance failures, and improper lobbying to secure government coverage for Soliris. Because both matters centered on the same misconduct, they were meaningfully linked under the insurance policies.
Did anyone go to jail or face criminal charges?
No. Despite serious allegations of Foreign Corrupt Practices Act violations, no individual executives faced criminal prosecution. The settlements imposed only corporate financial penalties, with no personal accountability for decision-makers.
What are orphan drugs and why are they so expensive?
Orphan drugs treat rare diseases affecting small patient populations. Pharmaceutical companies often charge extremely high prices for these drugs, arguing they need to recoup research costs from a limited customer base. However, critics say this pricing exploits vulnerable patients and allows companies to extract enormous profits from captive markets with no alternatives.
What can I do about pharmaceutical company misconduct?
Support organizations advocating for drug price reforms and stronger corporate accountability. Contact your elected representatives to demand legislation capping orphan drug prices, requiring transparency in pharmaceutical pricing, and imposing meaningful penalties for FCPA violations. Share information about cases like this to raise public awareness of how profit motives can override patient welfare.
Required bedtime reading about this case:
https://www.sec.gov/newsroom/press-releases/2020-149
https://www.sec.gov/files/litigation/admin/2020/34-89214.pdf
💡 Explore Corporate Misconduct by Category
Corporations harm people every day — from wage theft to pollution. Learn more by exploring key areas of injustice.
- 💀 Product Safety Violations — When companies risk lives for profit.
- 🌿 Environmental Violations — Pollution, ecological collapse, and unchecked greed.
- 💼 Labor Exploitation — Wage theft, worker abuse, and unsafe conditions.
- 🛡️ Data Breaches & Privacy Abuses — Misuse and mishandling of personal information.
- 💵 Financial Fraud & Corruption — Lies, scams, and executive impunity.
